Treatment of nonarteritic anterior ischemic optic neuropathy with intravitreal bevacizumab

J Neuroophthalmol. 2007 Sep;27(3):238-40. doi: 10.1097/WNO.0b013e31814b273d.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged, 80 and over
  • Angiogenesis Inhibitors / administration & dosage
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Cerebral Angiography
  • Female
  • Humans
  • Optic Neuropathy, Ischemic / complications
  • Optic Neuropathy, Ischemic / drug therapy*
  • Optic Neuropathy, Ischemic / physiopathology
  • Papilledema / drug therapy*
  • Papilledema / etiology
  • Papilledema / physiopathology
  • Retina / pathology
  • Retina / physiopathology
  • Retinal Artery / drug effects
  • Retinal Artery / pathology
  • Retinal Artery / physiopathology
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Vascular Endothelial Growth Factor A / metabolism
  • Vision, Low / drug therapy
  • Vision, Low / etiology
  • Vision, Low / physiopathology
  • Visual Fields / drug effects
  • Vitreous Body / drug effects

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab